5 known cases. View patent page →
Declaratory-judgment action listing the '219 patent among patents in the case, including 10,272,062; 10,736,866; 10,952,986; 7,851,506; and 8,731,963. Final disposition not confirmed.
Avadel-side Delaware action in which Flamel/Avadel asserted their modified-release GHB patent family, including U.S. 10,272,062 and 10,736,866 (parents of the '986 patent) and U.S. 10,952,986, against Jazz. The case was consolidated and dismissed by order on 2025-10-27 as part of the settlement.
Lead Hatch-Waxman/Lumryz case reported for US 10,736,866; the case went to jury trial in 2024 and was terminated on 2025-10-27.
Short-lived Delaware case reported for US 10,736,866; the retrieved table lists only Jazz Pharmaceuticals, Inc. as the legible party, so plaintiff/defendant roles are not stated.
Complaint pleads infringement of US 10,736,866 arising from Granules' ANDA/Paragraph IV certification. The narrative also mentions the '062 patent, but it cannot be decoded to a full patent number from the narrative.